| Title: | Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C |
| Authors: | Kawagishi, Naoki Browse this author |
| Suda, Goki Browse this author →KAKEN DB |
| Yamamoto, Yoshiya Browse this author |
| Baba, Masaru Browse this author |
| Furuya, Ken Browse this author |
| Maehara, Osamu Browse this author |
| Ohnishi, Shunsuke Browse this author |
| Yoshida, Sonoe Browse this author |
| Fu, Qingjie Browse this author |
| Yang, Zijian Browse this author |
| Hosoda, Shunichi Browse this author |
| Tokuchi, Yoshimasa Browse this author |
| Kitagataya, Takashi Browse this author |
| Ohara, Masatsugu Browse this author |
| Suzuki, Kazuharu Browse this author |
| Nakai, Masato Browse this author |
| Sho, Takuya Browse this author |
| Natsuizaka, Mitsuteru Browse this author |
| Ogawa, Koji Browse this author |
| Sakamoto, Naoya Browse this author |
| Keywords: | hepatitis C virus |
| direct-acting antiviral |
| angiopoietin-2 |
| hepatocellular carcinoma |
| recurrence |
| Issue Date: | Jan-2023 |
| Publisher: | MDPI |
| Journal Title: | Viruses-Basel |
| Volume: | 15 |
| Issue: | 1 |
| Start Page: | 181 |
| Publisher DOI: | 10.3390/v15010181 |
| Abstract: | Progressive liver fibrosis after anti-HCV treatment is a risk factor for HCC. Angiopoietin-2 (Ang2) is associated with non-regression of liver fibrosis after direct-acting antiviral (DAA). This study evaluated the predictive value of serum Ang2 levels for HCC occurrence or recurrence after DAA administration. In this retrospective study, 310 HCV-infected patients treated with DAAs in 2014-2020 were screened and evaluated for HCC occurrence or recurrence every three-six months. Multivariate Cox regression analysis revealed that age >= 75 years (HR: 2.92, 95% CI: 1.34-6.33; p = 0.007) and baseline Ang2 level >= 464 pg/mL (HR: 2.75, 95% CI: 1.18-6.37; p = 0.019) were significantly associated with HCC occurrence after DAA therapy. A high or low risk of HCC after DAA therapy could be distinguished by the combination of age and baseline Ang2 level. The cumulative incidences of de-novo HCC at two and four years were 0.8% and 3.8% in the low-risk group and 22.6% and 27.1% in the high-risk group, respectively. Baseline Ang2 level >= 402 pg/mL was significantly associated with HCC recurrence in patients who achieved sustained virological response with DAAs (HR: 3.68). In conclusion, serum Ang2 levels can predict HCC occurrence and recurrence after successful HCV eradication by DAAs. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/88804 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
